Showing 42,021 - 42,040 results of 74,822 for search '(( 50 ((ms decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 1.66s Refine Results
  1. 42021
  2. 42022
  3. 42023
  4. 42024
  5. 42025
  6. 42026

    Biomarker Benchmark - GSE37199 by Anna Guyer (1390293)

    Published 2016
    “…LPD1 CRPC patients had significantly poorer overall survival (median 10.7 months, CI-95% 4.2-17.2) than CRPC patients in LPD2 to 4 (median 26.5 months, CI-95% 18.1-34.9, p=0.00007). LPD 1 membership remained the strongest prognostic factor in a multivariate analysis (HR 5.0, CI-95% 2.1-11.9, p=0.0002). …”
  7. 42027

    Effects of Individual Micronutrients on CACO-2 Tight Junctional Proteins. by Mary Carmen Valenzano (484242)

    Published 2015
    “…This same procedure was used for quercetin (400μM), butyrate (5.0mM), berberine (100μM), and indole (1.0mM) at the concentrations that provided maximal barrier enhancement and for the same time periods used in Figs <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133926#pone.0133926.g001" target="_blank">1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0133926#pone.0133926.g002" target="_blank">2</a>. …”
  8. 42028

    Table 1_Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study.x... by Kaili Wang (2246485)

    Published 2025
    “…Demographic characteristics revealed a mean age of 57.0 years, male predominance (75%), average dialysis duration of 7.0 years, and mean body weight of 63.0 kg. …”
  9. 42029

    Table_1_Shifting Pathways of Stimulant Use Among Individuals With Opioid Use Disorder: A Retrospective Analysis of the Last Thirty Years.docx by Matthew S. Ellis (3390581)

    Published 2021
    “…Those initiating opioid/stimulant use from 1991 to 1995 had a mean average of 6.8 years between first and second drug exposure, which steadily decreased to 1.5 years between exposures in 2016–2020. …”
  10. 42030

    Supplementary Material for: Immunothrombosis and complement activation contribute to disease severity and adverse outcome in COVID-19 by Ruggeri T. (17354386)

    Published 2023
    “…Moreover, we provide evidence that in severe disease there is continued neutrophil and complement activation, as well as D-dimer formation and nucleosome release, whereas in mild and moderate disease all these markers decrease over time. …”
  11. 42031

    Optimizing the aggregate core structure enhances Pept-in antimicrobial potency. by Guiqin Wu (760045)

    Published 2023
    “…<b>D-H:</b> P2 variants which are incompatible with the cross-beta core structure: L6G (P2); V7S (P2); P2 variants which are more compatible with the cross-beta core structure more compatible: V7Y (P2), P2_A5F. …”
  12. 42032

    Flight capacities of yellow-legged hornet (<i>Vespa velutina nigrithorax</i>, Hymenoptera: Vespidae) workers from an invasive population in Europe by Daniel Sauvard (5352926)

    Published 2018
    “…Here, we carried out a study in which we quantified the flight capacities of <i>V. velutina</i> workers using computerized flight mills. …”
  13. 42033

    Image_1_Cystatin from the helminth Ascaris lumbricoides upregulates mevalonate and cholesterol biosynthesis pathways and immunomodulatory genes in human monocyte-derived dendritic... by Nathalie Acevedo (147971)

    Published 2024
    “…</p>Methods<p>moDC were generated from peripheral blood monocytes from six healthy human donors of Denmark, stimulated with 1 µM of Al-CPI, and cultured for 5 hours at 37°C. RNA was sequenced using TrueSeq RNA libraries and the NextSeq 550 v2.5 (75 cycles) sequencing kit (Illumina, Inc). …”
  14. 42034

    Circulating miRNAs in sepsis—A network under attack: An <i>in-silico</i> prediction of the potential existence of miRNA sponges in sepsis - Fig 4 by Catalin Vasilescu (258423)

    Published 2017
    “…The concentration of A will decrease more rapidly than that of B, because of the rising concentration of the predator X, who has a high reaction rate for A and B (0.9, respectively 0.5). …”
  15. 42035

    Table1_Shale Heavy Metal Isotope Records of Low Environmental O2 Between Two Archean Oxidation Events.XLSX by Chadlin M. Ostrander (12460062)

    Published 2022
    “…Yet, many details of this late-Archean O<sub>2</sub> story remain under-constrained, such as the extent, tempo, and location of O<sub>2</sub> accumulation. Here, we present a detailed Fe, Tl, and U isotope study of shales from a continuous sedimentary sequence deposited between ∼2.6 and ∼2.5 Ga and recovered from the Pilbara Craton of Western Australia (the Wittenoom and Mt. …”
  16. 42036

    Image_2_Cystatin from the helminth Ascaris lumbricoides upregulates mevalonate and cholesterol biosynthesis pathways and immunomodulatory genes in human monocyte-derived dendritic... by Nathalie Acevedo (147971)

    Published 2024
    “…</p>Methods<p>moDC were generated from peripheral blood monocytes from six healthy human donors of Denmark, stimulated with 1 µM of Al-CPI, and cultured for 5 hours at 37°C. RNA was sequenced using TrueSeq RNA libraries and the NextSeq 550 v2.5 (75 cycles) sequencing kit (Illumina, Inc). …”
  17. 42037

    Image_3_Cystatin from the helminth Ascaris lumbricoides upregulates mevalonate and cholesterol biosynthesis pathways and immunomodulatory genes in human monocyte-derived dendritic... by Nathalie Acevedo (147971)

    Published 2024
    “…</p>Methods<p>moDC were generated from peripheral blood monocytes from six healthy human donors of Denmark, stimulated with 1 µM of Al-CPI, and cultured for 5 hours at 37°C. RNA was sequenced using TrueSeq RNA libraries and the NextSeq 550 v2.5 (75 cycles) sequencing kit (Illumina, Inc). …”
  18. 42038

    Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4<sup>+</sup> Cell Rises in HIV-Infected Patients by Nicholas Funderburg (89116)

    Published 2010
    “…</p><h3>Methods and Findings</h3><p>Thirty maraviroc-treated patients from the Maraviroc versus Efavirenz Regimens as Initial Therapy (MERIT) study were randomly selected from among those who had CCR5-tropic (R5) HIV on screening and achieved undetectable HIV RNA (<50 copies/mL) by Week 48. …”
  19. 42039

    Fig 4 - by Sonia Borao (18764889)

    Published 2024
    “…Line plots represent the average splicing efficiency in <i>Δsaf5</i> (red line) and wild type (blue line) strains. Genes with a decrease of 50% in splicing efficiency in <i>Δsaf5</i> compared with wild type strain in the first (left panel), second (middle panel) and third (right panel) intron are represented.…”
  20. 42040